Clinical Trial Update: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravenous or subcutaneous Mircera for anemia in dialysis patients has completed; this entry provides a trial result update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 3 | Status: COMPLETED